The renin-angiotensin aldosterone system and osteoporosis: findings from the Women’s Health Initiative

Laura D Carbone, S. Vasan, R. L. Prentice, Gregory A Harshfield, B. Haring, J. A. Cauley, K. C. Johnson

Research output: Contribution to journalArticle

Abstract

Summary: New users of RAAS inhibitors, including ACE inhibitors and ARBs, have a small increased risk for fracture in the first 3 years of use, with a reduced risk of fracture with longer duration of use. Introduction: Pharmacological inhibitors of the renin-angiotensin aldosterone system (RAAS) are used to treat hypertension. However, the relationship of these medications to osteoporosis is inconsistent, and no study has included simultaneous measurements of both incident fractures and bone mineral density (BMD). Methods: The association of RAAS inhibitor use (n = 131,793) with incident fractures in new users of these medications in women in the Women’s Health Initiative over a minimum median follow-up of 6.5 years was assessed by Cox proportional hazard models. The association of incident fractures by a cumulative duration of use of these medications (< 3 years.) and (> 3 years.) was also estimated. Subgroup analysis of fracture risk by RAAS inhibitor use confined to women with hypertension was also performed (n = 33,820). The association of RAAS inhibitor use with changes in BMD of the hip was estimated by linear regression in 8940 women with dual energy X-ray absorptiometry measurements. Results: There was no significant association between RAAS inhibitor use and all fractures in the final adjusted multivariable models including hip BMD (HR 0.86 (0.59, 1.24)). However, among users of RAAS inhibitors, including ACE inhibitors and angiotensin receptor blockers (ARBs), hazard ratios for all incident fracture sites in final multivariable models including hip BMD showed dramatic differences by duration of use, with short duration of use (3 years or less) associated with a marked increased risk for fracture (HR 3.28 (1.66, 6.48)) to (HR 6.23 (3.11, 12.46)) and use for more than 3 years associated with a reduced fracture risk (HR 0.40 (0.24, 0.68) to (HR 0.44 (0.20, 0.97)). Findings were similar in the subgroup of women with a history of hypertension. There was no significant change in BMD of the hip by RAAS inhibitor use. Conclusions: In postmenopausal women, use of RAAS inhibitors, including ACE inhibitors and ARBs, is associated with an increased risk for fracture among new users of these medications in the first 3 years of use. However, long-term use (> 3 years) is associated with a reduced risk. Consideration for fracture risk may be part of the decision-making process for initiation of these medications for other disease states.

Original languageEnglish (US)
Pages (from-to)2039-2056
Number of pages18
JournalOsteoporosis International
Volume30
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Women's Health
Renin-Angiotensin System
Osteoporosis
Bone Density
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Pelvic Bones
Hypertension
Hip
Photon Absorptiometry
Proportional Hazards Models
Linear Models
Decision Making
Pharmacology

Keywords

  • Aging
  • Fracture
  • Medication
  • Postmenopausal

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

The renin-angiotensin aldosterone system and osteoporosis : findings from the Women’s Health Initiative. / Carbone, Laura D; Vasan, S.; Prentice, R. L.; Harshfield, Gregory A; Haring, B.; Cauley, J. A.; Johnson, K. C.

In: Osteoporosis International, Vol. 30, No. 10, 01.10.2019, p. 2039-2056.

Research output: Contribution to journalArticle

Carbone, Laura D ; Vasan, S. ; Prentice, R. L. ; Harshfield, Gregory A ; Haring, B. ; Cauley, J. A. ; Johnson, K. C. / The renin-angiotensin aldosterone system and osteoporosis : findings from the Women’s Health Initiative. In: Osteoporosis International. 2019 ; Vol. 30, No. 10. pp. 2039-2056.
@article{2209d6696469481899f9684afae3a005,
title = "The renin-angiotensin aldosterone system and osteoporosis: findings from the Women’s Health Initiative",
abstract = "Summary: New users of RAAS inhibitors, including ACE inhibitors and ARBs, have a small increased risk for fracture in the first 3 years of use, with a reduced risk of fracture with longer duration of use. Introduction: Pharmacological inhibitors of the renin-angiotensin aldosterone system (RAAS) are used to treat hypertension. However, the relationship of these medications to osteoporosis is inconsistent, and no study has included simultaneous measurements of both incident fractures and bone mineral density (BMD). Methods: The association of RAAS inhibitor use (n = 131,793) with incident fractures in new users of these medications in women in the Women’s Health Initiative over a minimum median follow-up of 6.5 years was assessed by Cox proportional hazard models. The association of incident fractures by a cumulative duration of use of these medications (< 3 years.) and (> 3 years.) was also estimated. Subgroup analysis of fracture risk by RAAS inhibitor use confined to women with hypertension was also performed (n = 33,820). The association of RAAS inhibitor use with changes in BMD of the hip was estimated by linear regression in 8940 women with dual energy X-ray absorptiometry measurements. Results: There was no significant association between RAAS inhibitor use and all fractures in the final adjusted multivariable models including hip BMD (HR 0.86 (0.59, 1.24)). However, among users of RAAS inhibitors, including ACE inhibitors and angiotensin receptor blockers (ARBs), hazard ratios for all incident fracture sites in final multivariable models including hip BMD showed dramatic differences by duration of use, with short duration of use (3 years or less) associated with a marked increased risk for fracture (HR 3.28 (1.66, 6.48)) to (HR 6.23 (3.11, 12.46)) and use for more than 3 years associated with a reduced fracture risk (HR 0.40 (0.24, 0.68) to (HR 0.44 (0.20, 0.97)). Findings were similar in the subgroup of women with a history of hypertension. There was no significant change in BMD of the hip by RAAS inhibitor use. Conclusions: In postmenopausal women, use of RAAS inhibitors, including ACE inhibitors and ARBs, is associated with an increased risk for fracture among new users of these medications in the first 3 years of use. However, long-term use (> 3 years) is associated with a reduced risk. Consideration for fracture risk may be part of the decision-making process for initiation of these medications for other disease states.",
keywords = "Aging, Fracture, Medication, Postmenopausal",
author = "Carbone, {Laura D} and S. Vasan and Prentice, {R. L.} and Harshfield, {Gregory A} and B. Haring and Cauley, {J. A.} and Johnson, {K. C.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1007/s00198-019-05041-3",
language = "English (US)",
volume = "30",
pages = "2039--2056",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "10",

}

TY - JOUR

T1 - The renin-angiotensin aldosterone system and osteoporosis

T2 - findings from the Women’s Health Initiative

AU - Carbone, Laura D

AU - Vasan, S.

AU - Prentice, R. L.

AU - Harshfield, Gregory A

AU - Haring, B.

AU - Cauley, J. A.

AU - Johnson, K. C.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Summary: New users of RAAS inhibitors, including ACE inhibitors and ARBs, have a small increased risk for fracture in the first 3 years of use, with a reduced risk of fracture with longer duration of use. Introduction: Pharmacological inhibitors of the renin-angiotensin aldosterone system (RAAS) are used to treat hypertension. However, the relationship of these medications to osteoporosis is inconsistent, and no study has included simultaneous measurements of both incident fractures and bone mineral density (BMD). Methods: The association of RAAS inhibitor use (n = 131,793) with incident fractures in new users of these medications in women in the Women’s Health Initiative over a minimum median follow-up of 6.5 years was assessed by Cox proportional hazard models. The association of incident fractures by a cumulative duration of use of these medications (< 3 years.) and (> 3 years.) was also estimated. Subgroup analysis of fracture risk by RAAS inhibitor use confined to women with hypertension was also performed (n = 33,820). The association of RAAS inhibitor use with changes in BMD of the hip was estimated by linear regression in 8940 women with dual energy X-ray absorptiometry measurements. Results: There was no significant association between RAAS inhibitor use and all fractures in the final adjusted multivariable models including hip BMD (HR 0.86 (0.59, 1.24)). However, among users of RAAS inhibitors, including ACE inhibitors and angiotensin receptor blockers (ARBs), hazard ratios for all incident fracture sites in final multivariable models including hip BMD showed dramatic differences by duration of use, with short duration of use (3 years or less) associated with a marked increased risk for fracture (HR 3.28 (1.66, 6.48)) to (HR 6.23 (3.11, 12.46)) and use for more than 3 years associated with a reduced fracture risk (HR 0.40 (0.24, 0.68) to (HR 0.44 (0.20, 0.97)). Findings were similar in the subgroup of women with a history of hypertension. There was no significant change in BMD of the hip by RAAS inhibitor use. Conclusions: In postmenopausal women, use of RAAS inhibitors, including ACE inhibitors and ARBs, is associated with an increased risk for fracture among new users of these medications in the first 3 years of use. However, long-term use (> 3 years) is associated with a reduced risk. Consideration for fracture risk may be part of the decision-making process for initiation of these medications for other disease states.

AB - Summary: New users of RAAS inhibitors, including ACE inhibitors and ARBs, have a small increased risk for fracture in the first 3 years of use, with a reduced risk of fracture with longer duration of use. Introduction: Pharmacological inhibitors of the renin-angiotensin aldosterone system (RAAS) are used to treat hypertension. However, the relationship of these medications to osteoporosis is inconsistent, and no study has included simultaneous measurements of both incident fractures and bone mineral density (BMD). Methods: The association of RAAS inhibitor use (n = 131,793) with incident fractures in new users of these medications in women in the Women’s Health Initiative over a minimum median follow-up of 6.5 years was assessed by Cox proportional hazard models. The association of incident fractures by a cumulative duration of use of these medications (< 3 years.) and (> 3 years.) was also estimated. Subgroup analysis of fracture risk by RAAS inhibitor use confined to women with hypertension was also performed (n = 33,820). The association of RAAS inhibitor use with changes in BMD of the hip was estimated by linear regression in 8940 women with dual energy X-ray absorptiometry measurements. Results: There was no significant association between RAAS inhibitor use and all fractures in the final adjusted multivariable models including hip BMD (HR 0.86 (0.59, 1.24)). However, among users of RAAS inhibitors, including ACE inhibitors and angiotensin receptor blockers (ARBs), hazard ratios for all incident fracture sites in final multivariable models including hip BMD showed dramatic differences by duration of use, with short duration of use (3 years or less) associated with a marked increased risk for fracture (HR 3.28 (1.66, 6.48)) to (HR 6.23 (3.11, 12.46)) and use for more than 3 years associated with a reduced fracture risk (HR 0.40 (0.24, 0.68) to (HR 0.44 (0.20, 0.97)). Findings were similar in the subgroup of women with a history of hypertension. There was no significant change in BMD of the hip by RAAS inhibitor use. Conclusions: In postmenopausal women, use of RAAS inhibitors, including ACE inhibitors and ARBs, is associated with an increased risk for fracture among new users of these medications in the first 3 years of use. However, long-term use (> 3 years) is associated with a reduced risk. Consideration for fracture risk may be part of the decision-making process for initiation of these medications for other disease states.

KW - Aging

KW - Fracture

KW - Medication

KW - Postmenopausal

UR - http://www.scopus.com/inward/record.url?scp=85067791247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067791247&partnerID=8YFLogxK

U2 - 10.1007/s00198-019-05041-3

DO - 10.1007/s00198-019-05041-3

M3 - Article

AN - SCOPUS:85067791247

VL - 30

SP - 2039

EP - 2056

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 10

ER -